StockNews.AI
TLTFF
StockNews.AI
188 days

Theralase(R) Demonstrates Effective Treatment of Herpes

1. Theralase validates Ruvidar's effectiveness against Herpes Simplex Virus Type 1 in animals.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive validation increases investor confidence in Theralase's products, potentially enhancing stock value, similar to previous successful drug validations.

How important is it?

This validation could significantly impact Theralase's market position and future innovations, making it crucial for investors.

Why Long Term?

Validation suggests a viable product pipeline, which could yield sustained revenue growth over time, akin to other biotech advancements.

Related Companies

TLTFFTLT
Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS Newswire / February 12, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the previous University of Manitoba research has now been validated, proving that RuvidarTM is safe and effective in the inactivation of Herpes Simplex Virus, Type 1 ("HSV-1") in an animal model.

Related News